| All Releases |
|---|
 |
Progenics Announces Results of Methylnaltrexone Phase 3 Safety Study in Chronic, Non-Malignant Pain Patients
May 20, 2011
|
69.9 KB
|
| |
TARRYTOWN, N.Y., May 20, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today provided analyses of safety and efficacy endpoints from the 1,034-patient, one-year phase 3 safety study of methylnaltrexone bromide subcutaneous injection in non-malignant pain patients with opioid-induced constipation (OIC). At a fixed dose of 12...
|
|
|
Progenics Pharmaceuticals Announces First Quarter 2011 Financial Results
May 10, 2011
|
20.1 KB
|
| |
TARRYTOWN, N.Y., May 10, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced its results of operations for the quarter ended March 31.
"The most significant event of our first quarter was completing a license agreement for RELISTOR® with Salix Pharmaceuticals," said Mark R. Baker, Progenics' chief exe...
|
|
|
Progenics to Host First Quarter 2011 Financial Results Conference Call and Webcast May 10
May 9, 2011
|
8.5 KB
|
| |
TARRYTOWN, N.Y., May 9, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it will host a conference call and webcast to discuss its financial results for the first quarter of 2011 on Tuesday May 10, 2011 at 8:30 a.m. ET.
To participate in the conference call, please dial 888-262-8720 (domestic) or 9...
|
|
|
Progenics Pharmaceuticals to Webcast Upcoming Presentations
Apr 4, 2011
|
10.4 KB
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that Mark
Baker, the Company's chief executive officer, will deliver company
updates at the 10th Annual Needham Healthcare Conference on Tuesday,
April 5, 2011 at 4:00pm ET, and at BioCentury's Future Leaders in the
...
|
|
|
Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2010 Financial Results
Mar 15, 2011
|
21.2 KB
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the fourth quarter and year ended December 31,
2010.
Financial Results
Net loss for the fourth quarter was $18.8 million or $0.57, basic and
...
|
|
|
Progenics Pharmaceuticals Announces Changes in Executive Responsibilities
Mar 9, 2011
|
12.3 KB
|
| |
– Mark R. Baker named chief executive officer –
– Founder Paul J. Maddon, M.D., Ph.D. appointed vice chairman –
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it
has appointed Mark R. Baker chief executive officer. Prior...
|
|
|
Progenics Reports Positive Preliminary Data from Ongoing Phase 1 Clinical Study of PSMA ADC
Feb 17, 2011
|
13.5 KB
|
| |
- Data Presented at Genitourinary Cancers Symposium -
TARRYTOWN, N.Y. & ORLANDO, Fla.--(BUSINESS WIRE)--
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today reported positive
preliminary data from an ongoing phase 1 study of PSMA ADC, an
antibody-drug conjugate (ADC) designed to selectively...
|
|
|
Progenics Pharmaceuticals and Salix Pharmaceuticals Announce Worldwide License Agreement for RELISTOR®
Feb 7, 2011
|
21.7 KB
|
| |
– RELISTOR Currently Marketed as First-in-Class Treatment for
Opioid-Induced Constipation in Advanced Illness Patients –
– Supplemental NDA Submission Planned in 2011 to Potentially
Expand Market to Chronic, Non-Malignant Pain –
– Phase 3 Trial of Oral RELISTOR in Chronic, Non-Mali...
|
|
|
Pfizer Inc and Progenics Alert Physicians and Patients to Information Related to Triad Group Alcohol Prep Products Included In U.S. RELISTOR Kit Packaging
Jan 25, 2011
|
10.9 KB
|
| |
NEW YORK & TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Pfizer Inc and Progenics Pharmaceuticals, Inc. have learned of a United
States market recall of alcohol prep pads and swabs manufactured by the
Triad Group. In the interest of patient safety, Pfizer and Progenics are
alerting U.S. patients and physicians to Triad’s re...
|
|
|
Progenics Pharmaceuticals Announces Phase 2 Clinical Trial of Subcutaneous Methylnaltrexone in Japan by Ono Pharmaceutical
Nov 16, 2010
|
16.5 KB
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the
initiation of a phase 2 clinical trial of subcutaneous methylnaltrexone
in Japan by its collaborator, Ono Pharmaceutical Co., Ltd. (OSE-TYO:
4528). The drug, designated ONO-3849 in Japan, is being evaluated for
...
|
|
|
Progenics Pharmaceuticals Announces Third Quarter 2010 Financial Results
Nov 8, 2010
|
25.8 KB
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the third quarter and nine months ended
September 30, 2010.
Net loss for the third quarter of 2010 was $17.1 million or $0.52, basic
and diluted, per share, comp...
|
|
|
Progenics Awarded $4.1 Million NIH Grant to Advance Novel C. Difficile Antibody Therapy
Oct 6, 2010
|
15.4 KB
|
| |
TARRYTOWN, N.Y., Oct 06, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the award
of a grant totaling $4,143,652 from the National Institutes of Health
(NIH) for Progenics' program to develop novel monoclonal antibodies to
treat Clostridium difficile (C. difficile) infection. C.
...
|
|
|
Progenics Announces Approvals of New Ready-to-Use Pre-Filled Syringes for RELISTOR in U.S., E.U. and Canada
Sep 29, 2010
|
17.2 KB
|
| |
TARRYTOWN, N.Y., Sep 29, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the
U.S. Food and Drug Administration (FDA), along with the European
Medicines Agency (EMA) of the European Union (E.U.) and Health Canada,
the Canadian Regulatory Agency, have each approved single-use,
...
|
|
|
Progenics Extends Agreement with Pfizer for RELISTOR Commercialization
Sep 27, 2010
|
15.3 KB
|
| |
TARRYTOWN, N.Y., Sep 27, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced it has
extended its agreement with Wyeth (now a subsidiary of Pfizer Inc.) to
continue Wyeth's commercialization of RELISTOR(R)
(methylnaltrexone bromide) Subcutaneous Injection in the United States
through...
|
|
|
Progenics Announces Clinical Completion of Subcutaneous Methylnaltrexone Safety Study in Chronic Non-Malignant Pain Patients
Sep 21, 2010
|
16.2 KB
|
| |
TARRYTOWN, N.Y., Sep 21, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the
completion of the treatment phase of a 1,034-patient, one-year,
open-label, international, phase 3 safety study of methylnaltrexone
bromide subcutaneous injection in chronic, non-malignant pain patients
...
|
|
|
Progenics' Humanized Monoclonal Antibodies Significantly Improve Survival in an Animal Model of C. difficile-associated Disease
Sep 13, 2010
|
16.0 KB
|
| |
TARRYTOWN, N.Y. & BOSTON, Sep 13, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today presented
preclinical findings for its humanized monoclonal antibodies against the
disease-causing toxins produced by the bacterium Clostridium difficile
(C. difficile). C. difficile is the leading cause of
...
|
|
|
Progenics Pharmaceuticals Initiates Oral Methylnaltrexone Phase 3 Trial in Patients with Chronic Non-Cancer Pain
Sep 8, 2010
|
17.1 KB
|
| |
TARRYTOWN, N.Y., Sep 08, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced the
initiation of an international 700-patient, phase 3 trial of oral
methylnaltrexone in patients with chronic, non-cancer pain who are
experiencing constipation as a result of their opioid-pain management
...
|
|
|
Progenics Pharmaceuticals to Present Preclinical Study of Novel Monoclonal Antibodies Against C. difficile at 2010 ICAAC
Aug 31, 2010
|
13.7 KB
|
| |
TARRYTOWN, N.Y., Aug 31, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that the
Company will present preclinical findings for its humanized monoclonal
antibodies that bind and neutralize the potentially life-threatening
toxins produced by the bacterium, Clostridium difficile (C.
...
|
|
|
Progenics Pharmaceuticals Announces Second Quarter 2010 Financial Results
Aug 9, 2010
|
23.3 KB
|
| |
TARRYTOWN, N.Y., Aug 09, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the second quarter and six months ended June
30, 2010.
Net loss for the second quarter of 2010 was $15.2 million or $0.47,
basic and diluted, per share, compared to $15.2 million or $...
|
|
|
Progenics Announces Positive Opinion Issued by a Committee of the European Medicines Agency for Relistor in Pre-Filled Syringes
Aug 5, 2010
|
15.5 KB
|
| |
TARRYTOWN, N.Y., Aug 05, 2010 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the
Committee for Medicinal Products for Human Use (CHMP), the scientific
committee of the European Medicines Agency (EMA), has issued a positive
opinion for RELISTOR(R) (methylnaltrexone bromide) subcutaneous...
|
|
|
